Vlado Perkovic's Publications

The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial
Journal articles
2023
Diabetes, Obesity and Metabolism
Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Journal articles
2023
Circulation
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
Journal articles
2023
Diabetes, Obesity and Metabolism
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Journal articles
2023
Kidney Int
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Journal articles
2023
J Am Soc Nephrol
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
Journal articles
2023
J Am Soc Nephrol
Targeting APRIL in the Treatment of IgA Nephropathy.
Journal articles
2023
Clin J Am Soc Nephrol
Combination therapy with kidney protective therapies: optimizing the benefits?
Journal articles
2023
Curr Opin Nephrol Hypertens
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Journal articles
2023
Nephrology Dialysis Transplantation
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
Journal articles
2023
Circulation
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Journal articles
2023
Diabetes, Obesity and Metabolism
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
Journal articles
2023
Diabetes, Obesity and Metabolism
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials
Journal articles
2023
Nephrology Dialysis Transplantation
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Journal articles
2023
Journal of the American Heart Association
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Journal articles
2023
Nature Medicine
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials
Journal articles
2023
Kidney International
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
Journal articles
2023
Diabetes, Obesity and Metabolism
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Journal articles
2023
American Journal of Kidney Diseases
3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D
Journal articles
2023
Nephrology Dialysis Transplantation
4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY
Journal articles
2023
Nephrology Dialysis Transplantation
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Journal articles
2023
BMJ Open Diabetes Research and Care
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Journal articles
2023
Clinical journal of the American Society of Nephrology : CJASN
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis
Journal articles
2023
Nephrology Dialysis Transplantation
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Journal articles
2023
The Lancet
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Journal articles
2023
Kidney International Reports
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Journal articles
2023
Kidney International Reports

Vlado Perkovic's Publications

The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.

Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.

Targeting APRIL in the Treatment of IgA Nephropathy.

Combination therapy with kidney protective therapies: optimizing the benefits?

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D

4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country